Prime Medicine, Inc. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-05 meeting.
“On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 23, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 9, 2026, the record date for the Annual Meeting, the number of shares of the Company’s common stock, $0.00001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting was 180,615,889. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 140,384,724, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common St”
Shareholder Votes
Prime Medicine, Inc. shareholders approved To elect Michael Kelly and David Schenkein, M.D. as Class I Directors. at the 2026-06-05 meeting.
“On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 23, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 9, 2026, the record date for the Annual Meeting, the number of shares of the Company’s common stock, $0.00001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting was 180,615,889. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 140,384,724, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common St”
Earnings Releases
Prime Medicine, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $49.1 million for the three months ended March 31, 2026.
“Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.”
Allan Reine was appointed as member of the Board of Directors at Prime Medicine, Inc..
“The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director”
Allan Reine was appointed as Chief Executive Officer and principal executive officer at Prime Medicine, Inc..
“the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company”
Keith Gottesdiener resigned as President, Chief Executive Officer and principal executive officer at Prime Medicine, Inc..
“Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company”
Earnings Releases
Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2024.
“today reported financial results for the first quarter ended March 31, 2024”
Earnings Releases
Prime Medicine, Inc. reported the full year ended December 31, 2023 results: net income $198.1 million.
“Net loss was $198.1 million for the year ended December 31, 2023”
Allan Reine was appointed as Chief Financial Officer at Prime Medicine, Inc..
“On January 4, 2024, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Allan Reine as the Chief Financial Officer and the principal financial officer of the Company effective as of January 17, 2024.”
Earnings Releases
Prime Medicine, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 3, 2023, Prime Medicine, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.”
Earnings Releases
Prime Medicine, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $42.4 million for the three months ended June 30, 2023.
“Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.”
Shareholder Votes
Prime Medicine, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes:”
Shareholder Votes
Prime Medicine, Inc. shareholders approved Election of Michael Kelly and David Schenkein as Class I Directors at the 2023-06-14 meeting.
“Each of the following nominees was elected as a Class I Director to serve until the Company’s 2026 annual meeting of stockholders, and until his respective successor shall have been duly elected and qualified, based on the following votes:”
Jeff Marrazzo was appointed as Director at Prime Medicine, Inc..
“On May 10, 2023, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Jeff Marrazzo as a director of the Company.”
Earnings Releases
Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2023.
“Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the first quarter ended March 31, 2023.”
Earnings Releases
Prime Medicine, Inc. reported the year ended December 31, 2022 results: net income Net loss was $121.8 million for the year ended December 31, 2022.
“Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022”
Earnings Releases
Prime Medicine, Inc. reported the fourth quarter of 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022.
“Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022”
Earnings Releases
Prime Medicine, Inc. reported fourth quarter and full year ended December 31, 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022.
“Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.